News


August 5, 2019 - Inotrem announces FDA clearance of IND for the ASTONISH trial (Phase IIb) in septic shock patients to demonstrate nangibotide efficacy
___________________________________________________________________________________________

February 2019 - Publication by Hawchar et al. "Extracorporeal cytokine adsorption in septic shock: A proof of concept randomized, controlled pilot study":
  • "Overall SOFA scores did not differ between the groups"
  • "In the CytoSorb-group norepinephrine requirements and PCT concentration decreased significantly"
  • "There were no CytoSorb therapy-related adverse events"
  • "Regarding CRP concentration, the CytoSorb and Control groups did not differ significantly"
  • "Mortality was 50% in both groups"
___________________________________________________________________________________________

November 26, 2018 - Adrenomed AG closes a €24 mio series D financing round co-led by Wellington Partners and HBM Healthcare Investments as new investors. "The new funds will be used to execute a proof-of-concept clinical program of lead product candidate Adrecizumab in early septic shock"
___________________________________________________________________________________________

October 24, 2018 - In the publication "Effect of human recombinant alkaline phosphatase on 7-day creatinine clearance in patients with sepsis-associated acute kidney injury - A randomized clinical trial" Pickkers et al. conclude that "Among patients who were critically ill with sepsis-associated acute kidney injury, treatment with human recombinant alkaline phosphatase did not improve kidney function in the first week of treatment."
___________________________________________________________________________________________

March 19, 2018 - Publication by Ellett et al. "Diagnosis of sepsis from a drop of blood by measurement of spontaneous neutrophil motility in a microfluidic assay"
___________________________________________________________________________________________

November 13, 2017 - Canton of Zug/Switzerland - Death by sepsis
___________________________________________________________________________________________

October 2017 - 1abtik ag and Isanas AG selectively join forces to advance developments of therapies in the area of severe inflammatory diseases

___________________________________________________________________________________________

July 14, 2017 - "America has a $27 billion sepsis crisis"
___________________________________________________________________________________________

July 2017 - In the review "The immunopathology of sepsis and potential therapeutic targets" van der Poll et al. summarize and discuss the impact of biomarkers, the high relevance of the sepsis-induced devastating excessive inflammation phase as well as potential intervention points for therapy

___________________________________________________________________________________________

May 31, 2017 - "World’s Fastest Sepsis Test From Abionic Produces Result In Five Minutes When Tested In Patients At London And Zurich Hospitals"
___________________________________________________________________________________________

January 25, 2017 - "Sepsis drives more readmissions than medical conditions tracked by CMS"
"...sepsis accounts for more 30-day readmissions and is more costly than heart attacks, heart failure, chronic obstructive pulmonary disease and pneumonia ... If we, as a nation, place such high emphasis on reducing readmissions for the other four conditions, then we really need to look for opportunities to improve outcomes for sepsis, which has a higher rate of readmission than heart failure.," Mayr said. "People who survive an initial episode of sepsis often don’t do well. They return to the hospital frequently, accrue new health conditions and have significantly elevated death rates."
___________________________________________________________________________________________

January 13, 2017 - Pan-resistant pathogenic bacteria isolated that led to septic shock and death, which means that the need for developing a specific, efficient sepsis therapy increases even more
"... the Washoe County Health District in Reno, Nevada, was notified of a patient at an acute care hospital with carbapenem-resistant Enterobacteriaceae (CRE) that was resistant to all available antimicrobial drugs." ... "The patient developed septic shock and died in early September."
___________________________________________________________________________________________

July 2016 - Rapid, simple diagnosis of sepsis
"The qSOFA score (also known as quickSOFA) is a bedside prompt that may identify patients with suspected infection who are at greater risk for a poor outcome outside the intensive care unit (ICU). It uses three criteria, assigning one point for low blood pressure (SBP≤100 mmHg), high respiratory rate (≥22 breaths per min), or altered mentation (Glasgow coma scale <15). ... Based upon these findings, the Third International Consensus Definitions for Sepsis recommends qSOFA as a simple prompt to identify infected patients outside the ICU who are likely to be septic."